Archean Chemical Analyst Review 2027: Bromine Revenue Up 76%, ICICI Securities Trims Target to ₹620
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: Market
Archean Chemical Industries Stock Snapshot (17 Nov 2026 close)
- Current Market Price (CMP): ₹439.50
- 52-Week High / Low: ₹639.80 / ₹413.80
- Market Capitalisation: ₹5,425 crore
- P/E Ratio vs Industry P/E: 55.4 vs 33.3
- Latest Quarter (Q2 FY27) Revenue: ₹301.61 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹31.33 crore
Quick Answer: The Archean Chemical analyst review 2027 centres on a bromine recovery. ICICI Securities kept a Buy rating after Q2 FY27 but cut its target to ₹620 from ₹655 in November 2026, about 41% above the 17 November close of ₹439.50. Q2 FY27 consolidated income rose about 26% to ₹301.61 crore as bromine revenue jumped 76%, but industrial salt volumes fell and profit rose only about 8% to ₹31.33 crore. The stock is about 31% below its 52-week high, so the Archean Chemical share price target 2027 depends on bromine output and salt shipments recovering together.
The Archean Chemical analyst review 2027 covers India’s largest exporter of bromine and industrial salt, which runs marine chemical operations on the Gujarat coast. Readers searching for an Archean Chemical share price target 2027 will find a named Buy call with a large gap to the market price, after a year in which profit fell sharply.
Archean Chemical Industries closed at ₹439.50 on 17 November 2026, about 31% below its 52-week high of ₹639.80 and just 6% above its low of ₹413.80. This Archean Chemical analyst review 2027 covers the brokerage view, the September quarter, new businesses and the Archean Chemical stock outlook 2027.
Click Here – Get Free Investment Predictions
What Brokerages Say in the Archean Chemical Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| ICICI Securities | Buy | ₹620 (cut from ₹655) | November 2026 |
| ICICI Securities | Buy | ₹655 (raised from ₹640) | September 2026 |
| ICICI Securities | Buy | ₹640 | August 2026 |
ICICI Securities has kept a Buy rating through FY27. In September 2026 it named Archean its top specialty chemicals pick and raised the target to ₹655, expecting earnings to recover sharply from the second half of FY27. It estimated bromine revenue growth of about 37% a year and bromine EBITDA growth of about 42.5% a year as production and prices normalise after three weak years.
After Q2 FY27, the brokerage cut its target to ₹620, using an unchanged 16 times FY28 estimated EBITDA. That target is about 41% above the current price. The trim shows that near-term numbers came in softer than hoped, even as the long-term view held.
In the Archean Chemical analyst review 2027, ICICI Securities also highlights the planned silicon carbide power semiconductor business as part of the long-term case. That project is early, so most of the near-term target rests on bromine.
Q2 FY27 Results in the Archean Chemical Analyst Review 2027
| Quarter | Total Income | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹301.61 crore | ₹74.46 crore | ₹31.33 crore |
| Jun 2026 (Q1 FY27) | ₹332.81 crore | ₹72.87 crore | ₹30.35 crore |
| Mar 2026 (Q4 FY26) | ₹306.33 crore | ₹49.08 crore | ₹12.23 crore |
| Dec 2025 (Q3 FY26) | ₹261.51 crore | ₹61.35 crore | ₹24.00 crore |
| Sep 2025 (Q2 FY26) | ₹239.56 crore | ₹68.98 crore | ₹29.04 crore |
Consolidated income rose about 25.9% to ₹301.61 crore, led by bromine. Bromine and derivatives revenue jumped 76% to about ₹127.5 crore on volumes up 29% to about 4,100 tonnes. Consolidated EBITDA grew only about 7.9%, and net profit rose about 8% to ₹31.33 crore.
The gap came from industrial salt, where some shipments were deferred because of softer PVC and caustic soda markets. H1 FY27 consolidated EBITDA fell about 5.1% to ₹147.3 crore. For the Archean Chemical analyst review 2027, bromine is clearly recovering, but salt held back profit.
How Archean Chemical Makes Money
- Bromine: extracted from sea brine at Hajipir in Gujarat and sold to pharma, agrochemical, flame retardant and oil field customers.
- Industrial salt: exported in bulk, mainly to chemical makers abroad who use it for chlor-alkali production.
- Sulphate of potash: a specialty fertiliser made from the same brine.
- New ventures: bromine derivatives through Acume Chemicals, specialty mud chemicals, silicon carbide power devices and zinc-bromide energy storage.
Annual revenue fell to about ₹1,108 crore in FY26 from ₹1,373 crore in FY24, and profit fell to about ₹105 crore from ₹319 crore as bromine prices and output dropped. The Archean Chemical analyst review 2027 is essentially a bet on that trend reversing.
Growth Triggers in the Archean Chemical Analyst Review 2027
- Bromine recovery: revenue up 76% and volume up 29% in Q2 FY27.
- Production guidance: the company guided to exit FY27 at 20,000 to 25,000 tonnes of annualised bromine output at a blended price near ₹300 per kg.
- Derivatives break-even: Acume Chemicals, the bromine derivatives unit, has reached EBITDA break-even.
- Semiconductor option: the silicon carbide power device venture is a long-term growth path.
- Low gearing: debt to equity of about 0.28 limits balance sheet strain, a support in the Archean Chemical analyst review 2027.
Key Risks in the Archean Chemical Analyst Review 2027
- Salt weakness: deferred shipments cut Q2 profit and could recur if PVC and caustic soda demand stays soft.
- Bromine prices: any fall in global bromine prices would hit margins directly.
- Weather and brine: monsoon dilution can reduce bromine output in some quarters.
- Valuation: a P/E near 55 is high because trailing profit is depressed.
- New venture risk: semiconductor and energy storage projects need capital and time.
- Domestic selling: domestic institutions cut their stake to 21.33% from 25.52%.
Compare Archean Chemical With Specialty Chemical Stocks on the Univest Screener
Archean Chemical Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (17 Nov 2026 close) | ₹439.50 |
| 52-Week High / Low | ₹639.80 / ₹413.80 |
| Market Capitalisation | ₹5,425 crore |
| P/E (TTM) vs Industry | 55.4 vs 33.3 |
| Price to Book | 2.76 |
| Book Value per Share | ₹159.02 |
| Return on Equity | 5.08% |
| Debt to Equity | 0.28 |
| Dividend Yield | 0.57% |
| FY26 Revenue / Net Profit | ₹1,108.0 crore / ₹105.4 crore |
The high P/E reflects a cyclical low in earnings rather than a premium valuation, and price to book value is a moderate 2.8. Return on equity of about 5% is far below the levels seen in FY24. The Archean Chemical analyst review 2027 hinges on whether profit returns towards those earlier levels.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 53.44% | 53.43% | -0.01 pts |
| Foreign Investors (FII) | 11.15% | 10.41% | -0.74 pts |
| Domestic Institutions (DII) | 25.52% | 21.33% | -4.19 pts |
| Public | 9.89% | 14.83% | +4.94 pts |
The promoter group, Chemikas Speciality LLP at 30.53% and Pendurthi Ranjit at 22.90%, holds a steady 53.43%. Domestic institutions sold about four percentage points, and retail investors bought. That shift added to price pressure during the Archean Chemical analyst review 2027 period.
What to Watch After the Archean Chemical Analyst Review 2027
- Bromine run rate: progress towards 20,000 to 25,000 tonnes of annualised output.
- Salt shipments: whether deferred cargoes are shipped in Q3 FY27.
- Bromine prices: how close realisations stay to ₹300 per kg.
- New ventures: milestones in silicon carbide devices and energy storage.
- Target revisions: any change to ICICI Securities’ ₹620 would reset the Archean Chemical share price target 2027.
Final Word on the Archean Chemical Analyst Review 2027
The Archean Chemical analyst review 2027 shows a bromine business that is clearly recovering, with revenue up 76% in Q2 FY27, held back by weak salt shipments. ICICI Securities keeps a Buy call at ₹620, about 41% above the price, but trimmed its target after the quarter.
The Archean Chemical stock outlook 2027 depends on bromine output reaching guidance, salt volumes recovering and new ventures progressing. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Archean Chemical analyst review 2027 show?
It shows a bromine-led recovery with a positive brokerage view. Q2 FY27 income rose about 25.9% to ₹301.61 crore as bromine revenue jumped 76%. ICICI Securities keeps a Buy rating with a ₹620 target.
What is the Archean Chemical share price target 2027 from brokerages?
ICICI Securities has a Buy rating with a ₹620 target, cut from ₹655 after Q2 FY27 in November 2026. It is based on 16 times FY28 estimated EBITDA. The stock closed at ₹439.50 on 17 November 2026, about 41% below that target.
Why did profit rise only 8% when income rose 26%?
Industrial salt volumes fell as some shipments were deferred because of weak PVC and caustic soda markets. Consolidated EBITDA rose only about 7.9%. Net profit was ₹31.33 crore against ₹29.04 crore a year earlier.
How does Archean Chemical make money?
It extracts bromine and industrial salt from sea brine in Gujarat and also makes sulphate of potash. Bromine goes to pharma, agrochemical and flame retardant buyers, while salt is mainly exported. FY26 revenue was about ₹1,108 crore.
Is Archean Chemical expensive, based on the Archean Chemical analyst review 2027?
The P/E of about 55.4 looks high because trailing profit is at a cyclical low. Price to book is about 2.8. Return on equity is about 5%, well below earlier years.
What risks does the Archean Chemical analyst review 2027 highlight?
The main risks are weak salt shipments, bromine price swings and weather affecting brine output. Domestic institutions cut their stake to 21.33% from 25.52%. New ventures in semiconductors and storage need capital.
What should investors track after the Archean Chemical analyst review 2027?
Track bromine output against the 20,000 to 25,000 tonne exit guidance and realisations near ₹300 per kg. Watch whether deferred salt shipments move in Q3 FY27. Any change to the ₹620 target will also matter.